Literature DB >> 23773203

Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials.

Hilary R Thomas1, Stephen E Gitelman.   

Abstract

Entities:  

Keywords:  T1D; autoimmunity; immunologic factors; prevention; review

Mesh：

Substances：

Year:  2013        PMID： 23773203      PMCID： PMC3748836          DOI： 10.1111/pedi.12040

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN： 1399-543X            Impact factor:   4.866


× No keyword cloud information.
  41 in total

Review 1.  A comprehensive review of interventions in the NOD mouse and implications for translation.

Authors:  Lisl K M Shoda; Daniel L Young; Saroja Ramanujan; Chan C Whiting; Mark A Atkinson; Jeffrey A Bluestone; George S Eisenbarth; Diane Mathis; Aldo A Rossini; Scott E Campbell; Richard Kahn; Huub T C Kreuwel
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

2.  Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.

Authors:  I Raz; A Avron; M Tamir; M Metzger; L Symer; R Eldor; I R Cohen; D Elias
Journal:  Diabetes Metab Res Rev       Date:  2007-05       Impact factor: 4.876

3.  Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.

Authors:  Kirsti Näntö-Salonen; Antti Kupila; Satu Simell; Heli Siljander; Tiina Salonsaari; Anne Hekkala; Sari Korhonen; Risto Erkkola; Jukka I Sipilä; Lotta Haavisto; Marja Siltala; Juhani Tuominen; Jari Hakalax; Heikki Hyöty; Jorma Ilonen; Riitta Veijola; Tuula Simell; Mikael Knip; Olli Simell
Journal:  Lancet       Date:  2008-09-22       Impact factor: 79.321

4.  Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Authors:  Kevan C Herold; Stephen Gitelman; Carla Greenbaum; Jennifer Puck; William Hagopian; Peter Gottlieb; Peter Sayre; Peter Bianchine; Emelita Wong; Vicki Seyfert-Margolis; Kasia Bourcier; Jeffrey A Bluestone
Journal:  Clin Immunol       Date:  2009-05-14       Impact factor: 3.969

5.  Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.

Authors:  Mark D Pescovitz; Carla J Greenbaum; Heidi Krause-Steinrauf; Dorothy J Becker; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Jennifer B Marks; Paula F McGee; Antoinette M Moran; Philip Raskin; Henry Rodriguez; Desmond A Schatz; Diane Wherrett; Darrell M Wilson; John M Lachin; Jay S Skyler
Journal:  N Engl J Med       Date:  2009-11-26       Impact factor: 91.245

6.  Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes.

Authors:  Jill M Norris; Xiang Yin; Molly M Lamb; Katherine Barriga; Jennifer Seifert; Michelle Hoffman; Heather D Orton; Anna E Barón; Michael Clare-Salzler; H Peter Chase; Nancy J Szabo; Henry Erlich; George S Eisenbarth; Marian Rewers
Journal:  JAMA       Date:  2007-09-26       Impact factor: 56.272

7.  Autoantibodies to IA-2beta improve diabetes risk assessment in high-risk relatives.

Authors:  P Achenbach; E Bonifacio; A J K Williams; A G Ziegler; E A M Gale; P J Bingley
Journal:  Diabetologia       Date:  2008-01-09       Impact factor: 10.122

8.  C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.

Authors:  Carlos E B Couri; Maria C B Oliveira; Ana B P L Stracieri; Daniela A Moraes; Fabiano Pieroni; George M N Barros; Maria Isabel A Madeira; Kelen C R Malmegrim; Maria C Foss-Freitas; Belinda P Simões; Edson Z Martinez; Milton C Foss; Richard K Burt; Júlio C Voltarelli
Journal:  JAMA       Date:  2009-04-15       Impact factor: 56.272

9.  Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

Authors:  B Keymeulen; M Walter; C Mathieu; L Kaufman; F Gorus; R Hilbrands; E Vandemeulebroucke; U Van de Velde; L Crenier; C De Block; S Candon; H Waldmann; A G Ziegler; L Chatenoud; D Pipeleers
Journal:  Diabetologia       Date:  2010-01-14       Impact factor: 10.122

10.  Expansion of human regulatory T-cells from patients with type 1 diabetes.

Authors:  Amy L Putnam; Todd M Brusko; Michael R Lee; Weihong Liu; Gregory L Szot; Taumoha Ghosh; Mark A Atkinson; Jeffrey A Bluestone
Journal:  Diabetes       Date:  2008-12-15       Impact factor: 9.461
View more
  4 in total

1.  Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.

Authors:  Kurt J Griffin; Paul A Thompson; Michael Gottschalk; Jennifer H Kyllo; Alex Rabinovitch
Journal:  Lancet Diabetes Endocrinol       Date:  2014-07-02       Impact factor: 32.069

Review 2.  New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity.

Authors:  Mohamad Mohty; Andrea Bacigalupo; Faouzi Saliba; Andreas Zuckermann; Emmanuel Morelon; Yvon Lebranchu
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

3.  Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis.

Authors:  Geoffrey D Keeler; Sandeep Kumar; Brett Palaschak; Emily L Silverberg; David M Markusic; Noah T Jones; Brad E Hoffman
Journal:  Mol Ther       Date:  2017-09-21       Impact factor: 11.454

4.  A novel platform for isotype-specific testing of autoantibodies.

Authors:  Kaylene L Carter; Anckia Treurnicht; Kara L Davis; Rajiv B Kumar; Brian J Feldman
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.